Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesInventoryLiabilities and Shareholders EquityMinority InterestNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

ImmunityBio (IBRX) Non-Current Deffered Revenue (2016 - 2018)

ImmunityBio (IBRX) has disclosed Non-Current Deffered Revenue for 5 consecutive years, with $2.7 million as the latest value for Q4 2018.

  • On a quarterly basis, Non-Current Deffered Revenue fell 17.62% to $2.7 million in Q4 2018 year-over-year; TTM through Dec 2018 was $2.7 million, a 17.62% decrease, with the full-year FY2018 number at $2.7 million, down 17.62% from a year prior.
  • Non-Current Deffered Revenue was $2.7 million for Q4 2018 at ImmunityBio, down from $2.9 million in the prior quarter.
  • In the past five years, Non-Current Deffered Revenue ranged from a high of $3.6 million in Q2 2017 to a low of $3000.0 in Q2 2015.
  • A 5-year average of $1.6 million and a median of $683000.0 in 2014 define the central range for Non-Current Deffered Revenue.
  • Biggest YoY gain for Non-Current Deffered Revenue was 6466.67% in 2016; the steepest drop was 77.87% in 2016.
  • ImmunityBio's Non-Current Deffered Revenue stood at $521000.0 in 2014, then soared by 62.19% to $845000.0 in 2015, then plummeted by 77.87% to $187000.0 in 2016, then surged by 1678.07% to $3.3 million in 2017, then decreased by 17.62% to $2.7 million in 2018.
  • Per Business Quant, the three most recent readings for IBRX's Non-Current Deffered Revenue are $2.7 million (Q4 2018), $2.9 million (Q3 2018), and $3.0 million (Q2 2018).